

Application No. 09/622,206

Reply to Advisory Action

REMARKS**Claim Amendments**

Claim 1 has been amended to delete the term "wherein the amino acid sequence is added adjacent to a C-terminal on an L chain of the Fab' antibody having a uniform isoelectric point." New Claim 22 has been added. The amended claim and new claim are supported by original claims. No new matter has been added.

Discussion of Obviousness Rejections

The Office has rejected claims 1-5 and 8 as allegedly obvious over a combination of references. Applicants respectfully traverse for the reasons discussed in the response filed on March 28, 2005, which is incorporated herein by reference. In addition, as regards claim 22, none of the cited references, either alone or in combination, suggests to those of ordinary skill in the art the presently claimed invention wherein the charge-modifying moiety is linked to the C-terminal of the light chain. The position where the detectable moiety and/or charge-modifying moiety is linked to the Fab' antibody is the single sulphydryl group in the hinge region in Karger et al., Fuchs et al., and Chen et al. Particularly, in Chen et al., the detectable moiety is linked at one end of charge-modifying moiety (synthetic oligonucleotides) and the antibody is linked via single sulphydryl group in the hinge region at the other end of the charge-modifying moiety.

Conclusion

The application is considered in good and proper form for allowance. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,



Xavier Pillai, Reg. No. 39,799
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson Avenue
Chicago, Illinois 60601-6780
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

Date: June 24, 2005